On Thursday, Timken Co. (TKR) announced that its board of directors has approved a plan to separate the company’s steel business from its bearing and power transmission business.
The separation will create two publicly-traded companies, with the steel company anticipating annual revenue of $1.7 billion, and the bearing and power transmission company having estimated annual revenue of $3.4 billion.
The company anticipates that the split of TKR will be tax-free for all shareholders, and expects the separation to be completed within 12 months.
TKR’s shares were up $1.79, or 3.06%, at market close on Thursday. YTD, the stock is up more than 19%.
Top Specialty Retail Companies To Watch In Right Now: TD Ameritrade Holding Corporation(AMTD)
TD Ameritrade Holding Corporation, through its subsidiaries, provides securities brokerage services and technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. The company?s offerings include TD Ameritrade for self-directed retail investors; TD Ameritrade Institutional, which provides brokerage and custody services to independent RIAs and their clients; thinkorswim that offers a suite of trading platforms serving self-directed and institutional traders, and money managers; and Investools, which provides investor education products and services for stock, option, foreign exchange, futures, mutual fund, and fixed-income investors. Its offerings also include Amerivest, an online advisory service that develops portfolios of exchange-traded funds to enable long-term investors pursue their financial goals; and TD Ameritrade Corporate Services, which provides self-directed brokerage services to employees and executives of corporations. In addition, the company offers various products and services, such as common and preferred stocks; exchange-traded funds; a range of option trades, including complex, multi-leg option strategies; futures trades in various commodities, stock indices, and currencies; and foreign exchange products. Further, it provides mutual funds; treasury, corporate, government agency, and municipal bonds; mortgage-backed securities and certificates of deposit; new issue securities; margin lending; and cash management services. Additionally, the company offers trustee, custodial, and other trust-related services to retirement plans; and cash sweep and deposit account products through third-party relationships. It provides its products and services through the Internet, network of retail branches, mobile trading applications, and interactive voice response and registered representatives via telephone. The company was founded in 1971 and is headquart ered in Omaha, Nebraska.
Advisors' Opinion:- [By Nicole Seghetti]
On top of the fund's expense ratio, it costs you money to trade ETFs. Because a commission is charged every time you place a buy or sell trade, finding a commission-free ETF platform will save you lots of money. Schwab's (NYSE: SCHW ) OneSource platform and TD Ameritrade (NYSE: AMTD ) offer access to some of the broadest lists of commission-free ETFs, with both platforms boasting more than 100 ETFs on their respective lists. Brokerage customers of Vanguard and Fidelity can buy and sell dozens of ETFs without incurring transaction fees. Unlike the other platforms, E*TRADE (NASDAQ: ETFC ) doesn't include products from some of the largest ETF providers, so its commission-free line up of funds comprises a lot of smaller ETFs.
Best Healthcare Technology Companies To Invest In Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
Disappointing FDA request
High-flying Sarepta Therapeutics (NASDAQ: SRPT ) encountered some turbulence this week. Shares in the biotech fell more than 18%. - [By Selena Maranjian]
Among holdings in which Soros Fund Management increased its stake was Sarepta Therapeutics (NASDAQ: SRPT ) . Sarepta has seen its stock soar more than eightfold over the past year, and some still see it as undervalued. Its stock fell a while back on news that after Sarepta petitioned the FDA for accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen, the FDA requested more information.�Management is optimistic about its recent interactions with the FDA, though.
Best Healthcare Technology Companies To Invest In Right Now: QSC AG (QSC)
QSC AG is a Germany-based telecommunications provider that offers enterprise customers and resellers a range of broadband communication services, from site networking to voice and data services. The Company operates in three business segments: Direct Sales; Indirect Sales, and Resellers. The Direct Sales segment (former Managed Services) focuses on larger and mid-size enterprises, and includes the business of subsidiaries INFO AG and IP Partner. The Indirect Sales segment focuses on regional partners that offer a portfolio of Information and Communication Technology (ICT) products, solutions and services, including Internet Service Providers (ISP), as well as voice and data services. The Resellers segment focuses on ISPs and telecommunication carriers that do not have an infrastructure of their own and primarily address residential customers. The Resellers segment also includes conventional voice business. In August 2013, it merged with INFO AG. Advisors' Opinion:- [By Jonathan Morgan]
QSC AG (QSC), a provider of telephony and data services to small and medium-sized businesses, jumped 9.5 percent after posting an increase in quarterly net income. Deutsche Boerse AG (DB1) retreated 2.7 percent after Equinet Bank AG downgraded the shares to sell.
Best Healthcare Technology Companies To Invest In Right Now: Commercial Metals Co (CMC)
Commercial Metals Company, incorporated on August 29, 1946, and its subsidiaries manufacture, recycle and market steel and metal products, related materials and services through a network, including steel mini mills, steel fabrication and processing plants, construction-related product warehouses, a copper tube mini mill, metal recycling facilities and marketing and distribution in the United States and in international markets. The Company Americas Division operates utilizing three segments: Americas Recycling, Americas Mills and Americas Fabrication. The Company�� International Division operates utilizing two segments: International Mill and International Marketing and Distribution, which includes all marketing and distribution operations located outside the United States, as well as two United States-based trading and distribution divisions, CMC Cometals, located in Fort Lee, New Jersey and CMC Cometals-Steel, located in Irving, Texas. In October 2013, Commercial Metals Company completed the sale of Howell Metal Company, to Mueller Copper Tube Products, Inc., a subsidiary of Mueller Industries, Inc.
Americas Recycling
The Americas Recycling segment processes scrap metals for use as a raw material by manufacturers of new metal products. This segment operates 33 scrap metal processing facilities with 16 locations in Texas, eight in Florida, two locations in Missouri and one location in each of Arkansas, Georgia, Kansas, Louisiana, North Carolina, Oklahoma and Tennessee. The Company purchases ferrous and nonferrous scrap metals, processed and unprocessed, from a range of sources in a range of forms for its metals recycling plants. Sources of metal for recycling include manufacturing and industrial plants, metal fabrication plants, electric utilities, machine shops, factories, railroads, refineries, shipyards, ordinance depots, demolition businesses, automobile salvage firms and wrecking firms.
The Company's scrap metal recycling plants typically consist of an o! ffice and warehouse building equipped with specialized equipment for processing both ferrous and nonferrous metal located on several acres of land that the Company uses for receiving, sorting, processing and storing metals. Several of the Company's scrap metal recycling plants use a small portion of their site or a nearby location to display and sell metal products that may be reused for their original purpose without further processing. Americas Recycling operates five shredding machines, three in Texas, one in Florida, and one in Oklahoma capable of pulverizing obsolete automobiles or other sources of scrap metal. The Company sells scrap metals to steel mills and foundries , aluminum sheets and ingot manufacturers, brass and bronze ingot makers, copper refineries and mills, secondary lead smelters, specialty steel mills, high temperature alloy manufacturers and other consumers.
Americas Mills
The Americas Mills segment includes the Company's domestic steel mills, including scrap metal shredders and processing facilities that directly support these mills and the domestic copper tube minimill. The Company conducts its Americas Mills operations through a network, which includes five steel mills, commonly referred to as minimills, that produce one or more of reinforcing bar, angles, flats, rounds, small beams, fence-post sections and other shapes; two scrap metal shredders and processing facilities that directly support the steel minimills, and The Company operates five steel minimills, which are located in Texas, Alabama, South Carolina, Arizona and Arkansas.
The Company's Texas minimill manufactures a line of bar size products, including reinforcing bar, angles, rounds, channels, flats, and special sections used primarily in building highways, reinforcing concrete structures and manufacturing. It sells primarily to the construction, service center, energy, petrochemical, and original equipment manufacturing industries. The Company's South Carolina minimill manufac! tures a l! ine of bar size products, which primarily includes steel reinforcing bar. The minimill also manufactures angles, rounds, squares, fence post sections and flats. The South Carolina minimill ships its products to customers located in the Southeast and mid-Atlantic regions, which include the states from Florida through southern New England.
Americas Fabrication
The Americas Fabrication segment consists of the Company's rebar fabrication operations, fence post manufacturing plants and construction-related and other product facilities. The Company conducts its Americas Fabrication operations through a network include steel plants that bend, cut, weld and fabricate steel, primarily reinforcing bar; warehouses that sell or rent products for the installation of concrete; plants that produce steel fence posts, and plants that heat-treat steel to strengthen and provide flexibility. The Company's Americas Fabrication segment operates 49 facilities that the Company considers to be engaged in the various aspects of steel fabrication.
The Company conducts steel fabrication activities in 16 locations in Texas, five each in California and South Carolina, three in Florida, two each in Arkansas, Colorado, Illinois, Louisiana, Mississippi, North Carolina, and Virginia, and one each in Arizona, Georgia, Nevada, New Mexico, Tennessee and Utah. Fabricated steel products are used primarily in the construction of commercial and non-commercial buildings, hospitals, convention centers, industrial plants, power plants, highways, bridges, arenas, stadiums, and dams. Generally, the Company sells fabricated steel in response to a bid solicitation from a construction contractor or the project owner. The Company sells and rent construction related products and equipment to concrete installers and other construction businesses.
The Company has 23 locations in Texas, Louisiana, Mississippi, and Oklahoma, where the Company store and sell these products which, with the exception of a s! mall port! ion of steel products, are purchased from third-party suppliers. The Company operates plants in Chicora, Pennsylvania, Struthers, Ohio and Pell City, Alabama which manufactures armor plate for military vehicles, high strength bar for the truck trailer industry and special bar quality steel for the energy market.
International Mill
The Company's International Mill segment includes the Company's minimill and recycling operations in Poland and its fabrication operations. The Company's subsidiary, CMC Zawiercie S.A. (CMCZ), owns a steel minimill and conducts its operations at Zawiercie, Poland. CMCZ, along with the Company's international recycling and fabrication operations, constitute the International Mill segment. CMCZ operates equipment similar to the Company's domestic steel minimills. The Company operates three rolling mills, one wire-rod mill and two bar mills including a specialty rod finishing mill. In addition, the Company operates a fabrication facility in Dabrowa Gornicza, Poland, that produces welded steel mesh, cold rolled wire rod and cold rolled reinforcing bar.
International Marketing and Distribution
International Marketing and Distribution includes international operations for the sales, distribution and processing of steel products, ferrous and nonferrous metals and other industrial products. In addition, the Company's International Marketing and Distribution segment includes the Company's United States based trading and distribution divisions, CMC Cometals and CMC Cometals Steel. The Company's International Marketing and Distribution business buys and sells primary and secondary metals, fabricated metals, semi-finished, long, flat steel products and other industrial products. The Company sells its products to customers, primarily manufacturers, in the steel, nonferrous metals, metal fabrication, chemical, refractory, construction and transportation businesses. This segment also operates a recycling facility in Singapore.
Advisors' Opinion:- [By Monica Gerson]
Analysts are expecting Commercial Metals Company (NYSE: CMC) to have earned $0.29 per share on revenue of $1.85 billion in the third quarter. Commercial Metals shares rose 0.78% to close at $18.09 yesterday.
- [By Monica Gerson]
Commercial Metals Company (NYSE: CMC) is estimated to report its Q3 earnings at $0.29 per share on revenue of $1.85 billion.
Finish Line (NASDAQ: FINL) is projected to report its Q1 earnings at $0.21 per share on revenue of $394.47 million.
- [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Commercial Metals Co.(CMC) said its fiscal second-quarter earnings surged as results in the steelmaker and recycler’s international mills business offset impacts from rising materials costs at its Americas units. Results missed expectations, but shares edged up 2.6% to $19.43 premarket.
- [By Ben Levisohn]
Then the upgrades started coming, and shares of U.S. Steel started to run. Its shares have returned 44% during the past three months, outpacing Commercial Metals Company’s (CMC) 21% gain, Steel Dynamics (STLD) 18% rise, and Nucor’s (NUE) 9.7% advance .
Best Healthcare Technology Companies To Invest In Right Now: Computer Programs and Systems Inc.(CPSI)
Computer Programs and Systems, Inc., a healthcare information technology company, designs, develops, markets, installs, and supports computerized information technology systems to small and midsize hospitals in the United States. Its enterprise-wide system automates the management of clinical and financial data across the primary functional areas of a hospital. The company offers services that enable customers to outsource certain data-related business processes in the areas of clinical care, revenue cycle management, cost control, and regulatory compliance. Its software products include Patient Management, which enables a hospital to identify a patient at any point in the healthcare delivery system, and to collect and maintain patient information through the process of patient care; Financial Accounting that provides various business office applications to track and coordinate information needed for managerial decision-making; and Clinical, which automates record keeping and reporting for a range of clinical functions, such as laboratory, radiology, physical therapy, respiratory care, and pharmacy. The company?s software products also comprise Patient Care that allows hospitals to create computerized patient files; and Enterprise Applications, which provide software applications that support its products for use in various areas of the hospital. In addition, it offers support and maintenance services; business management services, including electronic billing, statement processing, accounts receivable management, payroll processing, contract management, and insurance services; and system implementation and training services, such as conversion and training. Further, the company sells computer hardware, peripherals, forms, and office supplies. It serves acute care community hospitals; and small specialty hospitals that focus on medical areas, such as surgery, rehabilitation, and psychiatry. The company was founded in 1979 and is headquartere d in Mobile, Alabama.
Advisors' Opinion:- [By John Udovich]
In the wake of the Obamacare�fiasco, small cap healthcare information systems stock Computer Programs & Systems, Inc (NASDAQ: CPSI) has put in a good performance, meaning its worth taking a closer look at the stock along with the performance of large cap players like Cerner Corporation (NASDAQ: CERN) and McKesson Corporation (NYSE: MCK) and small cap Quality Systems, Inc (NASDAQ: QSII).
- [By Sally Jones]
Both CSP Inc. (CPSI) and ITT Educational Services Inc. (ESI) have struggled in the last year. Their revenues are way down as of the second quarter, year over year. Richard Blum�� Blum Capital Partners LP continues to trim sinking education companies where the company is 10% owner, and John Rogers of Ariel Capital Management cuts a long-held defense company that delivered high gains over five years.
Best Healthcare Technology Companies To Invest In Right Now: Performance Technologies Incorporated(PTIX)
Performance Technologies, Incorporated manufactures and supplies network communications solutions to carrier, government, defense, and original equipment manufacturer (OEM) markets. The company offers a suite of SEGway signaling solutions, including IP-centric STPs, gateways, edges, and network applications that provide signaling, routing, IP migration, gateway capabilities, SIP bridging, and core-to-edge distributed intelligence. It also provides IPnexus application-ready systems, which are IP-native integrated platforms and element management systems; Xpress, a portfolio of SIP-based applications and enabling infrastructure for next-generation network architectures; and universal signaling point and SP2000 products. The company markets its products through its direct sales forces, as well as through OEMs, value added resellers, distributors, and systems integrators worldwide. Performance Technologies, Incorporated was founded in 1981 and is headquartered in Rochester, Ne w York.
Advisors' Opinion:- [By Roberto Pedone]
Another stock that's starting to move within range of a big breakout trade is Performance Technologies (PTIX), which is a supplier of advanced network communications solutions to carrier, government and OEM markets. This stock has been red hot so far in 2013, with shares up huge by 275%.
If you take a look at the chart for Performance Technologies, you'll notice that this stock has been trending sideways and consolidating for the last three months and change, with shares moving between $2.50 on the downside and $3.97 on the upside. Shares of PTIX have now started to spike higher back above its 50-day moving average of $2.92 a share with bullish upside volume flows. This spike is quickly pushing shares of PTIX within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in PTIX if it manages to break out above some key overhead resistance levels at $3.40 to $3.79 a share, and then once it takes out its 52-week high at $3.97 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 167,669 shares. If that breakout hits soon, then PTIX will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $6 to $7 a share.
Traders can look to buy PTIX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support around $2.50 a share. One can also buy PTIX off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment